Current Report Filing (8-k)
July 13 2016 - 8:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
July 13, 2016
Ekso Bionics Holdings, Inc.
(Exact
Name of Registrant as specified in its charter)
Nevada
|
|
000-55442
|
|
99-0367049
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s name or former address,
if change since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02
|
Results of Operations and Financial Conditions
|
On July 13, 2016,
Ekso Bionics Holdings, Inc. (the “Company”) will participate in Cantor Fitzgerald’s 2
nd
Annual Healthcare
Conference in New York City. The Company is scheduled to present at 11:45 a.m. ET. A live audio webcast with accompanying slides
will be available on the investors section of the Company’s website at www.eksobionics.com. The webcast replay will be available
following the conclusion of the presentation.
|
Item 7.01
|
Regulation FD Disclosure
|
The information
disclosed above under Item 2.02 with respect to the investor presentation is incorporated herein by reference.
The information
contained in this report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended, or incorporated by reference into any filing of the Company, whether made before or after
the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Max Scheder-Bieschin
|
|
|
Name:
|
Max Scheder-Bieschin
|
|
Title:
|
Chief Financial Officer
|
Dated: July 13, 2016
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024